Condition: Systemic Lupus Erythematosus · Lupus Nephritis · Autoimmune Diseases · Sponsor: Essen Biotech
This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients suffering from resistant systemic lupus erythematosus can tolerate.
This description comes directly from the study's public registry record.
Rhoda M Smith, Phd · +12077706670 · clinical-trials@essen-biotech.com
Always discuss trial participation with your own doctor first.
| District One Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06350110